

Terry S Elton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9697703/publications.pdf>

Version: 2024-02-01

13
papers

903
citations

1163117

8
h-index

1281871

11
g-index

14
all docs

14
docs citations

14
times ranked

1883
citing authors

#	ARTICLE	IF	CITATIONS
1	Regulation of the MIR155 host gene in physiological and pathological processes. <i>Gene</i> , 2013, 532, 1-12.	2.2	405
2	Experimental validation of miRNA targets. <i>Methods</i> , 2008, 44, 47-54.	3.8	315
3	Trisomy-21 gene dosage over-expression of miRNAs results in the haploinsufficiency of specific target proteins. <i>RNA Biology</i> , 2010, 7, 540-547.	3.1	74
4	miR-802 regulates human angiotensin II type 1 receptor expression in intestinal epithelial C2BBe1 cells. <i>American Journal of Physiology - Renal Physiology</i> , 2010, 299, G632-G642.	3.4	29
5	Experimental procedures to identify and validate specific mRNA targets of miRNAs. <i>EXCLI Journal</i> , 2015, 14, 758-90.	0.7	20
6	Alternative RNA Processing of Topoisomerase II β in Etoposide-Resistant Human Leukemia K562 Cells: Intron Retention Results in a Novel C-Terminal Truncated 90-kDa Isoform. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 360, 152-163.	2.5	16
7	hsa-miR-9-3p and hsa-miR-9-5p as Post-Transcriptional Modulators of DNA Topoisomerase II β in Human Leukemia K562 Cells with Acquired Resistance to Etoposide. <i>Molecular Pharmacology</i> , 2020, 97, 159-170.	2.3	12
8	The Novel C-terminal Truncated 90-kDa Isoform of Topoisomerase II β (TOP2 β /90) Is a Determinant of Etoposide Resistance in K562 Leukemia Cells via Heterodimerization with the TOP2 β /170 Isoform. <i>Molecular Pharmacology</i> , 2018, 93, 515-525.	2.3	11
9	CRISPR/Cas9 Genome Editing of the Human Topoisomerase II β Intron 19 5' Splice Site Circumvents Etoposide Resistance in Human Leukemia K562 Cells. <i>Molecular Pharmacology</i> , 2021, 99, 226-241.	2.3	9
10	Effects of DNA topoisomerase II β splice variants on acquired drug resistance. , 2020, 3, 161-170.		7
11	Use of CRISPR/Cas9 with homology-directed repair to silence the human topoisomerase II β intron-19 5' splice site: Generation of etoposide resistance in human leukemia K562 cells. <i>PLoS ONE</i> , 2022, 17, e0265794.	2.5	3
12	Intronic Polyadenylation in Acquired Cancer Drug Resistance Circumvented by Utilizing CRISPR/Cas9 with Homology-Directed Repair: The Tale of Human DNA Topoisomerase II β . <i>Cancers</i> , 2022, 14, 3148.	3.7	2
13	Alternative RNA Processing as a Determinant of Acquired Resistance to the Anticancer Drug Etoposide in Human Leukemia K562 Cells. <i>FASEB Journal</i> , 2019, 33, 675.3.	0.5	0